Ad
related to: what happened to crsp stocksuperstockscreener.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. But don't expect CRISPR to try to offload ...
There's a lot of growth on the way, and soon.
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for ...
Shares in Crispr Therapeutics (CRSP) fell 4% in Monday’s after-hours trading, after the gene-focused biopharma reported disappointing second quarter earning results.Specifically, second quarter ...
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session.
Ad
related to: what happened to crsp stocksuperstockscreener.com has been visited by 10K+ users in the past month